Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 104
Filter
1.
J Pediatr Adolesc Gynecol ; 35(6): 676-684, 2022 Dec.
Article in English | MEDLINE | ID: mdl-35830926

ABSTRACT

STUDY OBJECTIVES: Adolescent pregnancies and births in the United States have undergone dramatic declines in recent decades. We aimed to estimate the contribution of changes in 3 proximal behaviors to these declines among 14- to 18-year-olds for 2007-2017: 1) delays in age at first sexual intercourse, 2) declines in number of sexual partners, and 3) changes in contraceptive use, particularly uptake of long-acting reversible contraception (LARC). DESIGN: We adapted an existing iterative dynamic population model and parameterized it using 6 waves of the Centers for Disease Control and Prevention's Youth Risk Behavior Survey. We compared pregnancies from observed behavioral trends with counterfactual scenarios that assumed constant behaviors over the decade. We calculated outcomes by cause, year, and age. RESULTS: We found that changes in these behaviors could explain pregnancy reductions of 496,200, 78,500, and 40,700 over the decade, respectively, with total medical and societal cost savings of $9.71 billion, $1.54 billion, and $796 million. LARC adoption, particularly among 18-year-olds, could explain much of the improvement from contraception use. The 3 factors together did not fully explain observed birth declines; adding a 50% decline in sex acts per partner did. CONCLUSIONS: Delays in first sexual intercourse contributed the most to declining births over this decade, although all behaviors considered had major effects. Differences from earlier models could result from differences in years and ages covered. Evidence-based teen pregnancy prevention programs, including comprehensive sex education, youth-friendly reproductive health services, and parental and community support, can continue to address these drivers and reduce teen pregnancy.


Subject(s)
Pregnancy in Adolescence , Reproductive Health Services , Pregnancy , Female , Adolescent , United States , Humans , Pregnancy in Adolescence/prevention & control , Contraception , Risk-Taking , Sex Education , Sexual Behavior , Contraception Behavior
2.
Epidemiol Infect ; 146(9): 1071-1078, 2018 07.
Article in English | MEDLINE | ID: mdl-29739483

ABSTRACT

Giardia duodenalis is the most common intestinal parasite of humans in the USA, but the risk factors for sporadic (non-outbreak) giardiasis are not well described. The Centers for Disease Control and Prevention and the Colorado and Minnesota public health departments conducted a case-control study to assess risk factors for sporadic giardiasis in the USA. Cases (N = 199) were patients with non-outbreak-associated laboratory-confirmed Giardia infection in Colorado and Minnesota, and controls (N = 381) were matched by age and site. Identified risk factors included international travel (aOR = 13.9; 95% CI 4.9-39.8), drinking water from a river, lake, stream, or spring (aOR = 6.5; 95% CI 2.0-20.6), swimming in a natural body of water (aOR = 3.3; 95% CI 1.5-7.0), male-male sexual behaviour (aOR = 45.7; 95% CI 5.8-362.0), having contact with children in diapers (aOR = 1.6; 95% CI 1.01-2.6), taking antibiotics (aOR = 2.5; 95% CI 1.2-5.0) and having a chronic gastrointestinal condition (aOR = 1.8; 95% CI 1.1-3.0). Eating raw produce was inversely associated with infection (aOR = 0.2; 95% CI 0.1-0.7). Our results highlight the diversity of risk factors for sporadic giardiasis and the importance of non-international-travel-associated risk factors, particularly those involving person-to-person transmission. Prevention measures should focus on reducing risks associated with diaper handling, sexual contact, swimming in untreated water, and drinking untreated water.


Subject(s)
Giardiasis/etiology , Adolescent , Adult , Aged , Aged, 80 and over , Bayes Theorem , Case-Control Studies , Child , Child, Preschool , Colorado/epidemiology , Female , Giardiasis/epidemiology , Giardiasis/transmission , Humans , Infant , Infant, Newborn , Logistic Models , Male , Middle Aged , Minnesota/epidemiology , Odds Ratio , Retrospective Studies , Risk Factors , Young Adult
3.
Vaccine ; 33(30): 3571-9, 2015 Jul 09.
Article in English | MEDLINE | ID: mdl-26044495

ABSTRACT

BACKGROUND: Evidence-based interventions to improve influenza vaccine coverage among pregnant women are needed, particularly among those who remain unvaccinated late into the influenza season. Improving rates of antenatal tetanus, diphtheria and acellular pertussis (Tdap) vaccination is also needed. PURPOSE: To test the effectiveness of a practice-, provider-, and patient-focused influenza and Tdap vaccine promotion package on improving antenatal influenza and Tdap vaccination in the obstetric setting. METHODS: A cluster-randomized trial among 11 obstetric practices in Georgia was conducted in 2012-2013. Intervention practices adopted the intervention package that included identification of a vaccine champion, provider-to-patient talking points, educational brochures, posters, lapel buttons, and iPads loaded with a patient-centered tutorial. Participants were recruited from December 2012-April 2013 and included 325 unvaccinated pregnant women in Georgia. Random effects regression models were used to evaluate primary and secondary outcomes. RESULTS: Data on antenatal influenza and Tdap vaccine receipt were obtained for 300 (92.3%) and 291 (89.5%) women, respectively. Although antenatal influenza and Tdap vaccination rates were higher in the intervention group than the control group, improvements were not significant (For influenza: risk difference (RD)=3.6%, 95% confidence interval (CI): -4.0%, 11.2%; for Tdap: RD=1.3%, 95% CI: -10.7%, 13.2%). While the majority of intervention package components were positively associated with antenatal vaccine receipt, a provider's recommendation was the factor most strongly associated with actual receipt, regardless of study group or vaccine. CONCLUSIONS: The intervention package did not significantly improve antenatal influenza or Tdap vaccine coverage. More research is needed to determine what motivates women remaining unvaccinated against influenza late into the influenza season to get vaccinated. Future research should quantify the extent to which clinical interventions can bolster a provider's recommendation for vaccination. This study is registered with clinicaltrials.gov, study ID NCT01761799.


Subject(s)
Diphtheria-Tetanus-acellular Pertussis Vaccines/immunology , Influenza Vaccines/immunology , Influenza, Human/prevention & control , Pregnancy Complications, Infectious/prevention & control , Vaccination/methods , Adolescent , Adult , Diphtheria-Tetanus-acellular Pertussis Vaccines/administration & dosage , Female , Georgia , Humans , Influenza Vaccines/administration & dosage , Middle Aged , Pregnancy , Vaccination/statistics & numerical data , Young Adult
4.
Neurology ; 72(17): 1465-72, 2009 Apr 28.
Article in English | MEDLINE | ID: mdl-19398702

ABSTRACT

OBJECTIVE: To determine if changes in brain metabolites are observed during early HIV infection and correlate these changes with immunologic alterations. METHODS: Eight subjects with early HIV infection, 9 HIV-seronegative controls, and 10 chronically HIV-infected subjects without neurologic impairment underwent 1H magnetic resonance spectroscopy. Subjects with early stage infection were identified near the time of HIV seroconversion and imaged within 60 days of an evolving Western blot, while still having detectable plasma virus. Subjects had blood drawn for viral RNA and T cell quantification. RESULTS: Both N-acetylaspartate (NAA) and Glx (glutamate + glutamine) were decreased in the frontal cortical gray matter of seropositive subjects. NAA levels were found to be decreased in the centrum semiovale white matter of chronically HIV-infected subjects, but not in those with early infection. Both HIV-infected cohorts demonstrated a lower number of CD4+ T lymphocytes and a higher number of CD8+ T lymphocytes in their blood. Lower NAA levels in the frontal cortex of subjects with early infection were associated with an expansion of CD8+ T cells, especially effector CD8+ T cells. CONCLUSIONS: These results verify metabolism changes occurring in the brain early during HIV infection. Lower NAA and Glx levels in the cortical gray matter suggests that HIV causes neuronal dysfunction soon after infection, which correlates to the expansion of CD8+ T cells, specifically to an activated phenotype. Utilizing magnetic resonance spectroscopy to track NAA levels may provide important information on brain metabolic health while allowing better understanding of the virus-host interactions involved in CNS functional deficits.


Subject(s)
AIDS Dementia Complex/metabolism , Brain/metabolism , Magnetic Resonance Spectroscopy/methods , Neurons/metabolism , T-Lymphocytes/metabolism , AIDS Dementia Complex/diagnosis , AIDS Dementia Complex/immunology , Adult , Aspartic Acid/analogs & derivatives , Aspartic Acid/analysis , Aspartic Acid/metabolism , Biomarkers/analysis , Biomarkers/metabolism , Brain/immunology , Brain/physiopathology , CD4-CD8 Ratio , Disease Progression , Early Diagnosis , Frontal Lobe/immunology , Frontal Lobe/metabolism , Frontal Lobe/physiopathology , Glutamic Acid/analysis , Glutamic Acid/metabolism , HIV Seropositivity/complications , Humans , Immunophenotyping , Middle Aged , Neurons/immunology , T-Lymphocytes/immunology
5.
Math Comput Model ; 49(7-8): 1653-1663, 2009 Apr.
Article in English | MEDLINE | ID: mdl-20161307

ABSTRACT

We propose a model for HCMV infection in healthy and immunosuppressed patients. First, we present the biological model and formulate a system of ordinary differential equations to describe the pathogenesis of primary HCMV infection in immunocompetent and immunosuppressed individuals. We then investigate how clinical data can be applied to this model. Approximate parameter values for the model are derived from data available in the literature and from mathematical and physiological considerations. Simulations with the approximated parameter values demonstrates that the model is capable of describing primary, latent, and secondary (reactivated) HCMV infection. Reactivation simulations with this model provide a window into the dynamics of HCMV infection in (D-R+) transplant situations, where latently-infected recipients (R+) receive transplant tissue from HCMV-naive donors (D-).

6.
J Biol Dyn ; 2(4): 357-85, 2008 Oct.
Article in English | MEDLINE | ID: mdl-19495424

ABSTRACT

A system of ordinary differential equations is formulated to describe the pathogenesis of HIV infection, wherein certain features that have been shown to be important by recent experimental research are incorporated in the model. These include the role of CD4+ memory cells that serve as a major reservoir of latently infected cells, a critical role for T-helper cells in the generation of CD8 memory cells capable of efficient recall response, and stimulation by antigens other than HIV. A stability analysis illustrates the capability of this model in admitting multiple locally asymptotically stable (locally a.s.) off-treatment equilibria.We show that this more biologically detailed model can exhibit the phenomenon of transient viremia experienced by some patients on therapy with viral load levels suppressed below the detection limit. We also show that the loss of CD4+ T-cell help in the generation of CD8+ memory cells leads to larger peak values for the viral load during transient viremia. Censored clinical data is used to obtain parameter estimates. We demonstrate that using a reduced set of 16 free parameters, obtained by fixing some parameters at their population averages, the model provides reasonable fits to the patient data and, moreover, that it exhibits good predictive capability. We further show that parameter values obtained for most clinical patients do not admit multiple locally a.s off-treatment equilibria. This suggests that treatment to move from a high viral load equilibrium state to an equilibrium state with a lower (or zero) viral load is not possible for these patients.


Subject(s)
HIV Infections/immunology , HIV Infections/virology , HIV/immunology , Immunity/immunology , Models, Immunological , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/virology , HIV Antigens/immunology , HIV Infections/drug therapy , Humans , Reproducibility of Results , Viral Load/immunology , Viremia/immunology , Virus Activation/immunology
7.
Bull Math Biol ; 69(2): 563-84, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17211735

ABSTRACT

We consider longitudinal clinical data for HIV patients undergoing treatment interruptions. We use a nonlinear dynamical mathematical model in attempts to fit individual patient data. A statistically-based censored data method is combined with inverse problem techniques to estimate dynamic parameters. The predictive capabilities of this approach are demonstrated by comparing simulations based on estimation of parameters using only half of the longitudinal observations to the full longitudinal data sets.


Subject(s)
Antiretroviral Therapy, Highly Active/methods , Data Interpretation, Statistical , HIV Infections/drug therapy , HIV-1 , Models, Biological , CD4 Lymphocyte Count , Cohort Studies , Drug Administration Schedule , HIV Infections/immunology , Humans , Longitudinal Studies , Predictive Value of Tests , Viral Load
8.
J Virol ; 77(3): 2081-92, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12525643

ABSTRACT

Cellular immune responses play a critical role in the control of human immunodeficiency virus type 1 (HIV-1); however, the breadth of these responses at the single-epitope level has not been comprehensively assessed. We therefore screened peripheral blood mononuclear cells (PBMC) from 57 individuals at different stages of HIV-1 infection for virus-specific T-cell responses using a matrix of 504 overlapping peptides spanning all expressed HIV-1 proteins in a gamma interferon-enzyme-linked immunospot (Elispot) assay. HIV-1-specific T-cell responses were detectable in all study subjects, with a median of 14 individual epitopic regions targeted per person (range, 2 to 42), and all 14 HIV-1 protein subunits were recognized. HIV-1 p24-Gag and Nef contained the highest epitope density and were also the most frequently recognized HIV-1 proteins. The total magnitude of the HIV-1-specific response ranged from 280 to 25,860 spot-forming cells (SFC)/10(6) PBMC (median, 4,245) among all study participants. However, the number of epitopic regions targeted, the protein subunits recognized, and the total magnitude of HIV-1-specific responses varied significantly among the tested individuals, with the strongest and broadest responses detectable in individuals with untreated chronic HIV-1 infection. Neither the breadth nor the magnitude of the total HIV-1-specific CD8+-T-cell responses correlated with plasma viral load. We conclude that a peptide matrix-based Elispot assay allows for rapid, sensitive, specific, and efficient assessment of cellular immune responses directed against the entire expressed HIV-1 genome. These data also suggest that the impact of T-cell responses on control of viral replication cannot be explained by the mere quantification of the magnitude and breadth of the CD8+-T-cell response, even if a comprehensive pan-genome screening approach is applied.


Subject(s)
Acquired Immunodeficiency Syndrome/immunology , Genome, Viral , HIV-1/immunology , T-Lymphocytes/immunology , Acquired Immunodeficiency Syndrome/virology , Amino Acid Sequence , Epitopes, T-Lymphocyte , Female , Gene Products, nef/immunology , HIV Core Protein p24/immunology , Humans , Interferon-gamma/biosynthesis , Male , Molecular Sequence Data , Peptide Fragments/immunology , Viral Load , nef Gene Products, Human Immunodeficiency Virus
9.
DNA Cell Biol ; 21(9): 671-8, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12396610

ABSTRACT

The HIV-1 regulatory proteins Tat and Rev and the accessory proteins Vpr, Vpu, and Vif are essential for viral replication, and their cytoplasmic production suggests that they should be processed for recognition by cytotoxic T lymphocytes. However, only limited data is available evaluating to which extent these proteins are targeted in natural infection and optimal cytotoxic T lymphocyte (CTL) epitopes within these proteins have not been defined. In this study, CTL responses against HIV-1 Tat, Rev, Vpr, Vpu, and Vif were analyzed in 70 HIV-1 infected individuals and 10 HIV-1 negative controls using overlapping peptides spanning the entire proteins. Peptide-specific interferon-gamma (IFN-gamma) production was measured by Elispot assay and flow-based intracellular cytokine quantification. HLA class I restriction and cytotoxic activity were confirmed after isolation of peptide-specific CD8+ T-cell lines. All regulatory and accessory proteins served as targets for HIV-1- specific CTL and multiple CTL epitopes were identified in functionally important regions of these proteins. In certain individuals HIV-1-specific CD8+ T-cell responses to these accessory and regulatory proteins contributed up to a third to the magnitude of the total HIV-1-specific CTL response. These data indicate that despite the small size of these proteins regulatory and accessory proteins are targeted by CTL in natural HIV-1 infection, and contribute importantly to the total HIV-1-specific CD8+ T-cell responses. These findings are relevant for the evaluation of the specificity and breadth of immune responses during acute and chronic#10; infection, and will be useful for the design and testing of candidate human immunodeficiency virus (HIV) vaccines.


Subject(s)
HIV Infections/immunology , HIV-1/immunology , T-Lymphocytes, Cytotoxic/immunology , Viral Regulatory and Accessory Proteins/immunology , CD8-Positive T-Lymphocytes/immunology , Epitopes , Humans , Interferon-gamma/metabolism
10.
Transpl Infect Dis ; 4(1): 31-40, 2002 Mar.
Article in English | MEDLINE | ID: mdl-12123424

ABSTRACT

Viral pathogens are important causes of morbidity following transplantation. Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections represent two major viral complications in transplant recipients. Recent advances in methodology have led to a better understanding of host immune responses directed against chronic viral infections. We review the nature of antiviral immunity involved in control of CMV and EBV. Viral mechanisms of immune evasion and immunotherapeutic strategies in the transplantation setting will also be addressed.


Subject(s)
Cytomegalovirus Infections/etiology , Epstein-Barr Virus Infections/etiology , Postoperative Complications , Transplantation , Animals , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Chronic Disease , Cytomegalovirus/immunology , Cytomegalovirus Infections/immunology , Cytomegalovirus Infections/therapy , Disease Models, Animal , Epstein-Barr Virus Infections/immunology , Epstein-Barr Virus Infections/therapy , Herpesvirus 4, Human/immunology , Humans , Immunotherapy , T-Lymphocytes, Cytotoxic/immunology
11.
J Virol ; 75(21): 10200-7, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11581388

ABSTRACT

Immediate treatment of acute human immunodeficiency virus type 1 (HIV-1) infection has been associated with subsequent control of viremia in a subset of patients after therapy cessation, but the immune responses contributing to control have not been fully defined. Here we examined neutralizing antibodies as a correlate of viremia control following treatment interruption in HIV-1-infected individuals in whom highly active antiretriviral therapy (HAART) was initiated during early seroconversion and who remained on therapy for 1 to 3 years. Immediately following treatment interruption, neutralizing antibodies were undetectable with T-cell-line adapted strains and the autologous primary HIV-1 isolate in seven of nine subjects. Env- and Gag-specific antibodies as measured by enzyme-linked immunosorbent assay were also low or undetectable at this time. Despite this apparent poor maturation of the virus-specific B-cell response during HAART, autologous neutralizing antibodies emerged rapidly and correlated with a spontaneous downregulation in rebound viremia following treatment interruption in three subjects. Control of rebound viremia was seen in other subjects in the absence of detectable neutralizing antibodies. The results indicate that virus-specific B-cell priming occurs despite the early institution of HAART, allowing rapid secondary neutralizing-antibody production following treatment interruption in a subset of individuals. Since early HAART limits viral diversification, we hypothesize that potent neutralizing-antibody responses to autologous virus are able to mature and that in some persons these responses contribute to the control of plasma viremia after treatment cessation.


Subject(s)
Acquired Immunodeficiency Syndrome/drug therapy , Antiretroviral Therapy, Highly Active , HIV Antibodies/blood , HIV-1/immunology , Viremia/drug therapy , Acquired Immunodeficiency Syndrome/immunology , Acute Disease , Humans , T-Lymphocytes, Cytotoxic/immunology , Viremia/immunology
12.
Immunol Lett ; 79(1-2): 109-16, 2001 Nov 01.
Article in English | MEDLINE | ID: mdl-11595297

ABSTRACT

Cytotoxic T lymphocytes (CTL) play a central role in containment of HIV infection. Evasion of the immune response by CTL escape is associated with progression to disease. It is therefore hypothesised that transmitted viruses encode escape mutations within epitopes that are required for successful control of viraemia. In order to test this hypothesis, escape through the dominant HLA-A2-restricted CTL epitope SLYNTVATL (p17 Gag residues 77-85 SL9) in the setting of mother-to-child-transmission (MTCT) was investigated. Initial data from two families in which the HIV-infected mother expressed HLA-A*0201 and had transmitted the virus to other family members were consistent with this hypothesis. In addition, analysis of the gag sequence phylogeny in one family demonstrated that CTL escape variants can be successfully transmitted both horizontally and vertically. To test the hypothesis further, a larger cohort of transmitting mothers (n=8) and non-transmitters (n=14) were studied. Variation within the SL9 epitope was associated with expression of HLA-A2 (P=0.04) but overall no clear link between variation from the SL9 consensus sequence and MTCT was established. However, the high level of background diversity within p17 Gag served to obscure any possible association between escape and MTCT. In conclusion, these studies highlighted the obstacles to demonstrating CTL escape arising at this particular epitope. Alternative strategies likely to be more definitive are discussed.


Subject(s)
Gene Products, gag/genetics , HIV Antigens/genetics , HIV Infections/immunology , HIV Infections/transmission , HLA-A2 Antigen , T-Lymphocytes, Cytotoxic/immunology , Viral Proteins , Amino Acid Sequence , Antigenic Variation , Child , Child, Preschool , Epitopes/genetics , Female , HIV/genetics , HIV/immunology , HIV Infections/genetics , HIV Infections/virology , HLA-A2 Antigen/genetics , Humans , Infectious Disease Transmission, Vertical , Male , Mutation , Pedigree , Phylogeny , Pregnancy , gag Gene Products, Human Immunodeficiency Virus
13.
J Virol ; 75(20): 9771-9, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11559810

ABSTRACT

Mounting evidence suggests that human immunodeficiency virus type 1 (HIV-1) Gag-specific T helper cells contribute to effective antiviral control, but their functional characteristics and the precise epitopes targeted by this response remain to be defined. In this study, we generated CD4(+) T-cell clones specific for Gag from HIV-1-infected persons with vigorous Gag-specific responses detectable in peripheral blood mononuclear cells. Multiple peptides containing T helper epitopes were identified, including a minimal peptide, VHAGPIAG (amino acids 218 to 226), in the cyclophilin binding domain of Gag. Peptide recognition by all clones examined induced cell proliferation, gamma interferon (IFN-gamma) secretion, and cytolytic activity. Cytolysis was abrogated by concanamycin A and EGTA but not brefeldin A or anti-Fas antibody, implying a perforin-mediated mechanism of cell lysis. Additionally, serine esterase release into the extracellular medium, a marker for cytolytic granules, was demonstrated in an antigen-specific, dose-dependent fashion. These data indicate that T helper cells can target multiple regions of the p24 Gag protein and suggest that cytolytic activity may be a component of the antiviral effect of these cells.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , HIV Infections/immunology , HIV-1 , Macrolides , Amino Acid Sequence , Anti-Bacterial Agents/pharmacology , Antibodies/pharmacology , Brefeldin A/pharmacology , CD4-Positive T-Lymphocytes/drug effects , Clone Cells , Cyclophilins/immunology , Cytotoxicity, Immunologic/drug effects , Dose-Response Relationship, Drug , Egtazic Acid/pharmacology , Epitopes/immunology , HIV Core Protein p24/chemistry , HIV Core Protein p24/immunology , HIV Core Protein p24/pharmacology , HIV Infections/virology , Humans , Interferon-gamma/immunology , Male , Middle Aged , Molecular Sequence Data , Protein Binding , T-Lymphocytes, Helper-Inducer/drug effects , T-Lymphocytes, Helper-Inducer/immunology , fas Receptor/immunology
14.
J Immunol ; 167(5): 2743-52, 2001 Sep 01.
Article in English | MEDLINE | ID: mdl-11509618

ABSTRACT

The HIV-1 accessory proteins Vpr, Vpu, and Vif are essential for viral replication, and their cytoplasmic production suggests that they should be processed for recognition by CTLs. However, the extent to which these proteins are targeted in natural infection, as well as precise CTL epitopes within them, remains to be defined. In this study, CTL responses against HIV-1 Vpr, Vpu, and Vif were analyzed in 60 HIV-1-infected individuals and 10 HIV-1-negative controls using overlapping peptides spanning the entire proteins. Peptide-specific IFN-gamma production was measured by ELISPOT assay and flow-based intracellular cytokine quantification. HLA class I restriction and cytotoxic activity were confirmed after isolation of peptide-specific CD8(+) T cell lines. CD8(+) T cell responses against Vpr, Vpu, and Vif were found in 45%, 2%, and 33% of HIV-1-infected individuals, respectively. Multiple CTL epitopes were identified in functionally important regions of HIV-1 Vpr and Vif. Moreover, in infected individuals in whom the breadth of HIV-1-specific responses was assessed comprehensively, Vpr and p17 were the most preferentially targeted proteins per unit length by CD8(+) T cells. These data indicate that despite the small size of these proteins Vif and Vpr are frequently targeted by CTL in natural HIV-1 infection and contribute importantly to the total HIV-1-specific CD8(+) T cell responses. These findings will be important in evaluating the specificity and breadth of immune responses during acute and chronic infection, and in the design and testing of candidate HIV vaccines.


Subject(s)
Gene Products, vpr/immunology , HIV Infections/immunology , HIV-1/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Case-Control Studies , Epitopes/genetics , Gene Products, vif/genetics , Gene Products, vif/immunology , Gene Products, vpr/genetics , HIV-1/genetics , Human Immunodeficiency Virus Proteins , Humans , In Vitro Techniques , Molecular Sequence Data , Peptide Fragments/genetics , Peptide Fragments/immunology , Viral Regulatory and Accessory Proteins/genetics , Viral Regulatory and Accessory Proteins/immunology , vif Gene Products, Human Immunodeficiency Virus , vpr Gene Products, Human Immunodeficiency Virus
15.
Clin Infect Dis ; 33(4): 570-2, 2001 Aug 15.
Article in English | MEDLINE | ID: mdl-11462197

ABSTRACT

In light of a recent report of 3 false-positive results of Epstein-Barr virus heterophile tests caused by HIV infection, we sought to assess the frequency of this occurrence. One hundred thirty-two positive heterophile antibody-tested serum samples were obtained from 2 tertiary care facilities in Boston to assess for HIV, and all tested negative for HIV plasma RNA. This study shows that false-positive results of heterophile tests are not frequently associated with primary HIV infection.


Subject(s)
Antibodies, Heterophile/blood , HIV Infections/diagnosis , Infectious Mononucleosis/diagnosis , False Positive Reactions , HIV Infections/virology , HIV-1/isolation & purification , Herpesvirus 4, Human/immunology , Humans , Infectious Mononucleosis/virology , RNA, Viral/blood
16.
Nature ; 412(6844): 334-8, 2001 Jul 19.
Article in English | MEDLINE | ID: mdl-11460164

ABSTRACT

Increasing evidence indicates that potent anti-HIV-1 activity is mediated by cytotoxic T lymphocytes (CTLs); however, the effects of this immune pressure on viral transmission and evolution have not been determined. Here we investigate mother-child transmission in the setting of human leukocyte antigen (HLA)-B27 expression, selected for analysis because it is associated with prolonged immune containment in adult infection. In adults, mutations in a dominant and highly conserved B27-restricted Gag CTL epitope lead to loss of recognition and disease progression. In mothers expressing HLA-B27 who transmit HIV-1 perinatally, we document transmission of viruses encoding CTL escape variants in this dominant Gag epitope that no longer bind to B27. Their infected infants target an otherwise subdominant B27-restricted epitope and fail to contain HIV replication. These CTL escape variants remain stable without reversion in the absence of the evolutionary pressure that originally selected the mutation. These data suggest that CTL escape mutations in epitopes associated with suppression of viraemia will accumulate as the epidemic progresses, and therefore have important implications for vaccine design.


Subject(s)
HIV Infections/transmission , HIV-1/genetics , Mutation , T-Lymphocytes, Cytotoxic/immunology , Adult , Child , DNA, Viral , Disease Progression , Epitopes, T-Lymphocyte/genetics , Female , HIV Infections/genetics , HIV Infections/immunology , HIV Infections/virology , HIV-1/immunology , HLA-B27 Antigen/immunology , Histocompatibility Testing , Humans , Infectious Disease Transmission, Vertical
17.
J Virol ; 75(14): 6279-91, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11413294

ABSTRACT

Cytotoxic T lymphocytes (CTL) target multiple epitopes in human immunodeficiency virus (HIV)-infected persons, and are thought to influence the viral set point. The extent to which HLA class I allele expression predicts the epitopes targeted has not been determined, nor have the relative contributions of responses restricted by different class I alleles within a given individual. In this study, we performed a detailed analysis of the CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7. The eight HIV-1-infected subjects studied included two subjects with acute HIV infection, five subjects with chronic HIV infection, and one long-term nonprogressor. Responses were heterogeneous with respect to breadth and magnitude of CTL responses in individuals of the same HLA type. Of the 27 tested epitopes that are presented by A2, A3, and B7, 25 were targeted by at least one person. However, there was wide variation in the number of epitopes targeted, ranging from 2 to 17. The A2-restricted CTL response, which has been most extensively studied in infected persons, was found to be narrowly directed in most individuals, and in no cases was it the dominant contributor to the total HIV-1-specific CTL response. These results indicate that HLA type alone does not predict CTL responses and that numerous potential epitopes may not be targeted by CTL in a given individual. These data also provide a rationale for boosting both the breadth and the magnitude of HIV-1-specific CTL responses by immunotherapy in persons with chronic HIV-1 infection.


Subject(s)
Epitopes, T-Lymphocyte/immunology , HIV Infections/immunology , HIV-1 , Histocompatibility Antigens Class I/immunology , T-Lymphocytes, Cytotoxic/immunology , Alleles , Chronic Disease , Epitopes, T-Lymphocyte/genetics , HIV Infections/virology , HLA-A1 Antigen/analysis , HLA-A2 Antigen/analysis , HLA-B7 Antigen/analysis , Humans
18.
AIDS ; 15 Suppl 2: S16-21, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11424972

ABSTRACT

Despite recent success with the use of highly active antiretroviral therapy, eradication of HIV type 1 appears beyond the capabilities of presently available therapy. Therefore, greater emphasis has been given to finding mechanisms that promote immunologic control of viral replication rather than eradication. Although the correlates of immune protection in HIV-1 infection remain undefined, increasing evidence indicates that HIV-1-specific cellular immune responses may play a critical role in antiviral control. Vigorous HIV-1-specific CD4+ T-helper cell and CD8+ cytotoxic T-lymphocyte responses may play a critical role in control of viral replication in the absence of antiretroviral therapy, which has been demonstrated in individuals with long-term nonprogressive infection. However, in chronic, progressive HIV-1 infection, virus-specific T-helper cell responses are typically weak or absent in all stages of disease, and HIV-1-specific cytotoxic T-lymphocyte responses wane over time, presumably due to the lack of HIV-1-specific T helper cells. Effective treatment of individuals during acute HIV-1 seroconversion syndrome appears to restore HIV-1-specific T-helper cell responses, which are otherwise only observed in persons with long-term nonprogressive infection. This observation, along with anecdotal reports of individuals successfully controlling viral replication after treating acute HIV-1 infection, provides immunologic rationale for structured treatment interruption and other immunotherapeutic approaches designed to augment HIV-1-specific immune responses.


Subject(s)
Acquired Immunodeficiency Syndrome/immunology , HIV-1/immunology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Helper-Inducer/immunology , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/virology , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/immunology , Anti-HIV Agents/pharmacology , Disease Progression , HIV-1/drug effects , Humans , T-Lymphocytes, Cytotoxic/virology , T-Lymphocytes, Helper-Inducer/virology , Th1 Cells/immunology , Th1 Cells/virology , Viremia/drug therapy , Viremia/immunology , Viremia/virology
19.
Proc Natl Acad Sci U S A ; 98(9): 5140-5, 2001 Apr 24.
Article in English | MEDLINE | ID: mdl-11309482

ABSTRACT

Certain HLA-B antigens have been associated with lack of progression to AIDS. HLA-B alleles can be divided into two mutually exclusive groups based on the expression of the molecular epitopes HLA-Bw4 and HLA-Bw6. Notably, in addition to its role in presenting viral peptides for immune recognition, the HLA-Bw4, but not HLA-Bw6, motif functions as a ligand for a natural killer cell inhibitory receptor (KIR). Here, we show that profound suppression of HIV-1 viremia is significantly associated with homozygosity for HLA-B alleles that share the HLA-Bw4 epitope. Furthermore, homozygosity for HLA-Bw4 alleles was also significantly associated with the ability to remain AIDS free and to maintain a normal CD4 T cell count in a second cohort of HIV-1-infected individuals with well defined dates of seroconversion. This association was independent of the presence of a mutation in CC chemokine receptor 5 (CCR5) associated with resistance to HIV-1 infection, and it was independent of the presence of HLA alleles that could potentially confound the results. We conclude that homozygosity for HLA-Bw4-bearing B alleles is associated with a significant advantage and that the HLA-Bw4 motif is important in AIDS pathogenesis.


Subject(s)
Acquired Immunodeficiency Syndrome/genetics , Acquired Immunodeficiency Syndrome/immunology , HIV-1/immunology , HLA-B Antigens/genetics , HLA-B Antigens/immunology , Homozygote , Viremia/immunology , Acquired Immunodeficiency Syndrome/virology , Adult , Alleles , CD4 Lymphocyte Count , Cohort Studies , Disease Progression , Epitopes/immunology , Female , Gene Frequency , HIV Seropositivity/genetics , HIV Seropositivity/immunology , HIV Seropositivity/virology , HIV-1/physiology , HLA-C Antigens/genetics , HLA-C Antigens/immunology , Humans , Killer Cells, Natural/immunology , Male , Middle Aged , Mutation/genetics , Receptors, CCR5/genetics , Receptors, Immunologic/immunology , Receptors, KIR , Time Factors , Viral Load , Viremia/genetics , Viremia/virology
20.
Proc Natl Acad Sci U S A ; 98(4): 1781-6, 2001 Feb 13.
Article in English | MEDLINE | ID: mdl-11172028

ABSTRACT

The HIV-1 regulatory proteins Rev and Tat are expressed early in the virus life cycle and thus may be important targets for the immune control of HIV-1-infection and for effective vaccines. However, the extent to which these proteins are targeted in natural HIV-1 infection as well as precise epitopes targeted by human cytotoxic T lymphocytes (CTL) remain to be defined. In the present study, 57 HIV-1-infected individuals were screened for responses against Tat and Rev by using overlapping peptides spanning the entire Tat and Rev proteins. CD8+ T cell responses against Tat and Rev were found in up to 19 and 37% of HIV-1-infected individuals, respectively, indicating that these regulatory proteins are important targets for HIV-1-specific CTL. Despite the small size of these proteins, multiple CTL epitopes were identified in each. These data indicate that Tat and Rev are frequently targeted by CTL in natural HIV-1 infection and may be important targets for HIV vaccines.


Subject(s)
Gene Products, rev/immunology , Gene Products, tat/immunology , HIV Infections/immunology , HIV-1/immunology , T-Lymphocytes, Cytotoxic/immunology , CD8-Positive T-Lymphocytes/immunology , Epitopes, T-Lymphocyte/immunology , HIV Infections/blood , Humans , Longitudinal Studies , Peptides/immunology , rev Gene Products, Human Immunodeficiency Virus , tat Gene Products, Human Immunodeficiency Virus
SELECTION OF CITATIONS
SEARCH DETAIL
...